![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: ZNF770 |
Gene summary for ZNF770 |
![]() |
Gene information | Species | Human | Gene symbol | ZNF770 | Gene ID | 54989 |
Gene name | zinc finger protein 770 | |
Gene Alias | PRO1914 | |
Cytomap | 15q14 | |
Gene Type | protein-coding | GO ID | GO:0006139 | UniProtAcc | Q6IQ21 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
54989 | ZNF770 | PTC05 | Human | Thyroid | PTC | 2.87e-25 | 1.03e+00 | 0.2065 |
54989 | ZNF770 | PTC06 | Human | Thyroid | PTC | 4.36e-27 | 1.04e+00 | 0.2057 |
54989 | ZNF770 | PTC07 | Human | Thyroid | PTC | 5.90e-48 | 7.82e-01 | 0.2044 |
54989 | ZNF770 | ATC09 | Human | Thyroid | ATC | 1.67e-04 | 5.79e-02 | 0.2871 |
54989 | ZNF770 | ATC12 | Human | Thyroid | ATC | 1.75e-10 | 1.11e-01 | 0.34 |
54989 | ZNF770 | ATC13 | Human | Thyroid | ATC | 1.39e-11 | 2.14e-01 | 0.34 |
54989 | ZNF770 | ATC1 | Human | Thyroid | ATC | 1.90e-03 | 6.42e-02 | 0.2878 |
54989 | ZNF770 | ATC2 | Human | Thyroid | ATC | 5.59e-07 | 3.01e-01 | 0.34 |
54989 | ZNF770 | ATC4 | Human | Thyroid | ATC | 3.64e-12 | 1.76e-01 | 0.34 |
54989 | ZNF770 | ATC5 | Human | Thyroid | ATC | 8.87e-16 | 2.44e-01 | 0.34 |
Page: 1 2 3 4 5 6 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 2 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
ZNF770 | SNV | Missense_Mutation | novel | c.73A>T | p.Arg25Trp | p.R25W | Q6IQ21 | protein_coding | deleterious(0) | probably_damaging(0.962) | TCGA-A7-A6VW-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | CR |
ZNF770 | SNV | Missense_Mutation | novel | c.2023N>T | p.His675Tyr | p.H675Y | Q6IQ21 | protein_coding | deleterious(0) | probably_damaging(0.997) | TCGA-AC-A3W7-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | femara | SD |
ZNF770 | SNV | Missense_Mutation | rs140429599 | c.1618G>C | p.Gly540Arg | p.G540R | Q6IQ21 | protein_coding | tolerated(0.1) | benign(0.125) | TCGA-AN-A0FW-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
ZNF770 | SNV | Missense_Mutation | novel | c.322C>G | p.Gln108Glu | p.Q108E | Q6IQ21 | protein_coding | tolerated(0.24) | benign(0.084) | TCGA-AQ-A7U7-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Targeted Molecular therapy | rituximab | CR |
ZNF770 | SNV | Missense_Mutation | rs768441646 | c.1877N>A | p.Arg626Gln | p.R626Q | Q6IQ21 | protein_coding | tolerated(1) | benign(0) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
ZNF770 | SNV | Missense_Mutation | novel | c.470N>C | p.Lys157Thr | p.K157T | Q6IQ21 | protein_coding | deleterious(0.01) | possibly_damaging(0.835) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
ZNF770 | SNV | Missense_Mutation | novel | c.1610N>C | p.Val537Ala | p.V537A | Q6IQ21 | protein_coding | tolerated(0.12) | benign(0.003) | TCGA-ZJ-AAXA-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
ZNF770 | SNV | Missense_Mutation | c.1981N>G | p.Thr661Ala | p.T661A | Q6IQ21 | protein_coding | deleterious(0.01) | benign(0.056) | TCGA-A6-6141-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Chemotherapy | 5-fu | SD | |
ZNF770 | SNV | Missense_Mutation | c.1528N>G | p.Lys510Glu | p.K510E | Q6IQ21 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-AA-3710-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
ZNF770 | SNV | Missense_Mutation | novel | c.1321N>C | p.Ser441Pro | p.S441P | Q6IQ21 | protein_coding | tolerated(0.15) | benign(0) | TCGA-AA-A00N-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD |
Page: 1 2 3 4 5 6 7 8 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |